

The genomic landscape of pediatric cancers: Implications

Science

363, 1170-1175

DOI: [10.1126/science.aaw3535](https://doi.org/10.1126/science.aaw3535)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Impacts of cannabinoid epigenetics on human development: reflections on Murphy et. al. "cannabinoid exposure and altered DNA methylation in rat and human sperm" epigenetics 2018; 13: 1208-1221.. Epigenetics, 2019, 14, 1041-1056. | 2.7 | 35 |
| 2 | Data sharing for clinical utility. Journal of Physical Education and Sports Management, 2019, 5, a004689. | 1.2 | 4 |
| 3 | Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia. Frontiers in Oncology, 2019, 9, 420. | 2.8 | 14 |
| 4 | Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors. International Journal of Molecular Sciences, 2019, 20, 2098. | 4.1 | 9 |
| 5 | Ushering in the next generation of precision trials for pediatric cancer. Science, 2019, 363, 1175-1181. | 12.6 | 41 |
| 6 | Are We Ill Because We Age?. Frontiers in Physiology, 2019, 10, 1508. | 2.8 | 41 |
| 7 | Circulating cell-free tumor DNA analysis in pediatric cancers. Molecular Aspects of Medicine, 2020, 72, 100819. | 6.4 | 24 |
| 8 | NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica, 2020, 139, 157-174. | 7.7 | 13 |
| 9 | Novel phenotypes observed in patients with <i>ETV6</i> -linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor. Journal of Medical Genetics, 2020, 57, 427-433. | 3.2 | 11 |
| 10 | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. Cancers, 2020, 12, 2714. | 3.7 | 27 |
| 11 | Paediatric Oncology at the Crossroads: A Call for Change. Pharmaceutical Medicine, 2020, 34, 297-300. | 1.9 | 5 |
| 12 | Genetic Predisposition to Solid Pediatric Cancers. Frontiers in Oncology, 2020, 10, 590033. | 2.8 | 31 |
| 13 | Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study. JCO Precision Oncology, 2020, 4, 926-936. | 3.0 | 9 |
| 14 | The Epigenetic Progenitor Origin of Cancer Reassessed: DNA Methylation Brings Balance to the Stem Force. Epigenomes, 2020, 4, 8. | 1.8 | 4 |
| 15 | Molecular karyotyping and gene expression analysis in childhood cancer patients. Journal of Molecular Medicine, 2020, 98, 1107-1123. | 3.9 | 5 |
| 16 | Fusing the Genetic Landscape of Infantile High-Grade Gliomas. Cancer Discovery, 2020, 10, 904-906. | 9.4 | 1 |
| 17 | News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43. | 9.6 | 35 |
| 18 | Physical exercise effects on metastasis: a systematic review and meta-analysis in animal cancer models. Cancer and Metastasis Reviews, 2020, 39, 91-114. | 5.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Compound Heterozygous Variants in Pediatric Cancers: A Systematic Review. <i>Frontiers in Genetics</i> , 2020, 11, 493. | 2.3 | 13 |
| 20 | Sequencing Strategies for Fusion Gene Detection. <i>BioEssays</i> , 2020, 42, 2000016. | 2.5 | 18 |
| 21 | PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. <i>Nucleic Acids Research</i> , 2021, 49, D1321-D1327. | 14.5 | 9 |
| 22 | Proteogenomics for pediatric brain cancer. <i>Biocell</i> , 2021, 45, 1459-1463. | 0.7 | 0 |
| 23 | Architecture of Cancer Therapies. , 2021, , 147-161. | | 0 |
| 24 | Tumors of the Liver in Children. , 2021, , 769-800. | | 0 |
| 25 | Precision medicine in pediatric solid cancers. <i>Seminars in Cancer Biology</i> , 2022, 84, 214-227. | 9.6 | 10 |
| 26 | Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 395-404. | 1.0 | 6 |
| 27 | Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. <i>Npj Precision Oncology</i> , 2021, 5, 69. | 5.4 | 81 |
| 28 | Role of CXCL12, TP53 and CYP1A1 gene polymorphisms in susceptibility to pediatric acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2021, 22, 659. | 1.8 | 2 |
| 29 | Immunometabolism: A "Hot" Switch for "Cold" Pediatric Solid Tumors. <i>Trends in Cancer</i> , 2021, 7, 751-774. | | 8 |
| 30 | Early-phenotype CAR-T cells for the treatment of pediatric cancers. <i>Annals of Oncology</i> , 2021, 32, 1366-1380. | 1.2 | 14 |
| 31 | The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development. <i>Cancers</i> , 2021, 13, 4324. | 3.7 | 22 |
| 32 | Pediatric Hematologic and Oncologic Emergencies. <i>Emergency Medicine Clinics of North America</i> , 2021, 39, 555-571. | 1.2 | 7 |
| 33 | Data-driven approaches to advance research and clinical care for pediatric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188571. | 7.4 | 5 |
| 34 | Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. <i>Blood Advances</i> , 2021, 5, 4864-4876. | 5.2 | 4 |
| 35 | Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children. <i>JAMA Oncology</i> , 2021, 7, 1281. | 7.1 | 4 |
| 37 | Introduction: specific disease areas. , 2021, , 43-262. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 38 | Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight, 2020, 5, . | 5.0 | 23 |
| 39 | Immune profiling of pediatric solid tumors. Journal of Clinical Investigation, 2020, 130, 3391-3402. | 8.2 | 27 |
| 42 | A role for club cells in smoking-associated lung adenocarcinoma. European Respiratory Review, 2021, 30, 210122. | 7.1 | 14 |
| 44 | Informatics Methods and Infrastructure Needed to Study Factors Associated with High Incidence of Pediatric Brain and Central Nervous System Tumors in Kentucky. Journal of Registry Management, 2020, 47, 127-134. | 0.1 | 1 |
| 45 | Acetylenic Synthetic Betulin Derivatives Inhibit Akt and Erk Kinases Activity, Trigger Apoptosis and Suppress Proliferation of Neuroblastoma and Rhabdomyosarcoma Cell Lines. International Journal of Molecular Sciences, 2021, 22, 12299. | 4.1 | 3 |
| 46 | Targeting tumor microenvironment and metastasis in children with solid tumors. Current Opinion in Pediatrics, 2022, 34, 53-60. | 2.0 | 7 |
| 47 | Liquid biopsies in pediatric oncology: opportunities and obstacles. Current Opinion in Pediatrics, 2022, 34, 39-47. | 2.0 | 5 |
| 48 | Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opinion on Drug Discovery, 2021, , 1-13. | 5.0 | 5 |
| 50 | Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clinical and Translational Oncology, 2022, , 1. | 2.4 | 1 |
| 51 | The oncogenic fusion landscape in pediatric CNS neoplasms. Acta Neuropathologica, 2022, 143, 427-451. | 7.7 | 22 |
| 52 | Cancer predisposing syndrome: a retrospective cohort analysis in a pediatric and multidisciplinary genetic cancer counseling unit. International Journal of Clinical Oncology, 2022, , 1. | 2.2 | 0 |
| 53 | Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies. Expert Review of Neurotherapeutics, 2022, 22, 209-219. | 2.8 | 1 |
| 55 | Molecular Markers of Pediatric Solid Tumors—Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions. Cells, 2022, 11, 1238. | 4.1 | 7 |
| 56 | Predicting amplification of <i>MYCN</i> using CpG methylation biomarkers in neuroblastoma. Future Oncology, 2021, 17, 4769-4783. | 2.4 | 5 |
| 57 | Exercise and Childhood Cancer—A Historical Review. Cancers, 2022, 14, 82. | 3.7 | 15 |
| 58 | Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes. Frontiers in Genetics, 2022, 13, 858396. | 2.3 | 6 |
| 60 | Proteogenomics for pediatric brain cancer.. Biocell, 2021, 45, 1459-1463. | 0.7 | 0 |
| 61 | Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO Precision Oncology, 2022, 6, e2100451. | 3.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 62 | Large-Scale Chromatin Rearrangements in Cancer. <i>Cancers</i> , 2022, 14, 2384. | 3.7 | 3 |
| 63 | Individualized discovery of rare cancer drivers in global network context. <i>ELife</i> , 2022, 11, . | 6.0 | 3 |
| 64 | Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210. | 1.2 | 6 |
| 65 | Caregiver Perspectives on Patient Participation in Biological Pediatric Cancer Research. <i>Children</i> , 2022, 9, 901. | 1.5 | 0 |
| 66 | Germline <i>De Novo</i> Mutations as a Cause of Childhood Cancer. <i>JCO Precision Oncology</i> , 2022, , . | 3.0 | 4 |
| 67 | Genetic Disorders with Predisposition to Paediatric Haematopoietic Malignanciesâ€”A Review. <i>Cancers</i> , 2022, 14, 3569. | 3.7 | 1 |
| 68 | Stemness Correlates Inversely with MHC Class I Expression in Pediatric Small Round Blue Cell Tumors. <i>Cancers</i> , 2022, 14, 3584. | 3.7 | 0 |
| 69 | In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. <i>Scientific Reports</i> , 2022, 12, . | 3.3 | 0 |
| 70 | Special Considerations in the Molecular Diagnostics of Pediatric Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 349-365. | 1.4 | 1 |
| 71 | Rare Inherited Cholestatic Disorders and Molecular Links to Hepatocarcinogenesis. <i>Cells</i> , 2022, 11, 2570. | 4.1 | 2 |
| 72 | Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents. <i>Frontiers in Pediatrics</i> , 0, 10, . | 1.9 | 3 |
| 73 | Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells. <i>Journal of Hematology and Oncology</i> , 2022, 15, . | 17.0 | 3 |
| 75 | Unified rhombic lip origins of group 3 and group 4 medulloblastoma. <i>Nature</i> , 2022, 609, 1012-1020. | 27.8 | 44 |
| 76 | Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. <i>Med</i> , 2022, , . | 4.4 | 6 |
| 77 | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 10 |
| 78 | Full Sails against Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16609. | 2.6 | 0 |
| 79 | Pancancer Analysis of the Prognostic and Immunotherapeutic Value of Progesterin and AdipoQ Receptor 4. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-24. | 1.3 | 1 |
| 80 | Epidemiology and Characteristics of Gastric Carcinoma in Childhoodâ€”An Analysis of Data from Population-Based and Clinical Cancer Registries. <i>Cancers</i> , 2023, 15, 317. | 3.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 81 | Pediatric biobanks to enhance clinical and translational research for children. <i>European Journal of Pediatrics</i> , 2023, 182, 1459-1468. | 2.7 | 2 |
| 82 | Oncogenic role for an EWSâ€“FLI1 suppressor. <i>Nature Cell Biology</i> , 0, , . | 10.3 | 0 |
| 84 | The emerging applications and advancements of Raman spectroscopy in pediatric cancers. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 0 |
| 85 | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664. | 4.5 | 2 |
| 86 | Promoting the application of pediatric radiomics via an integrated medical engineering approach. , 2023, 2, 302-311. | | 0 |
| 87 | Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. <i>Npj Precision Oncology</i> , 2023, 7, . | 5.4 | 10 |
| 88 | Roles of lncRNAs in childhood cancer: Current landscape and future perspectives. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 2 |
| 89 | <i>Pediatric Cancers</i> . , 2023, , 261-274. | | 0 |
| 90 | The Health Care Utilization and Medical Costs in Long-Term Follow-Up of Children Diagnosed With Leukemia, Solid Tumor, or Brain Tumor: Population-Based Study Using the National Health Insurance Claims Data. <i>JMIR Public Health and Surveillance</i> , 0, 9, e42350. | 2.6 | 4 |
| 91 | Diagnostic classification of childhood cancer using multiscale transcriptomics. <i>Nature Medicine</i> , 2023, 29, 656-666. | 30.7 | 6 |
| 93 | Prevalence of pathogenic variants in cancerâ€“predisposing genes in second cancer after childhood solid cancers. <i>Cancer Medicine</i> , 0, , . | 2.8 | 1 |
| 94 | Accelerating the understanding of cancer biology through the lens of genomics. <i>Cell</i> , 2023, 186, 1755-1771. | 28.9 | 9 |
| 95 | <i>Architecture of Cancer Therapies</i> . , 2023, , 535-547. | | 0 |
| 96 | Molecular genomic landscape of pediatric solid tumors in Chinese patients: implications for clinical significance. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , . | 2.5 | 0 |
| 97 | Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8324. | 4.1 | 0 |
| 98 | The Swedish childhood tumor biobank: systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden. <i>Journal of Translational Medicine</i> , 2023, 21, . | 4.4 | 3 |
| 99 | RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming. <i>Current Treatment Options in Oncology</i> , 2023, 24, 1088-1101. | 3.0 | 2 |
| 101 | <i>Indications for Gene Testing for At Risk Families and Genetic Risk Calculation</i> . , 2023, , 1-8. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 102 | Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19. | | 0 |
| 103 | Pediatric solid tumors. , 2023, , 427-477. | | 0 |
| 104 | Chromosomal Instability in Genome Evolution: From Cancer to Macroevolution. <i>Biology</i> , 2023, 12, 671. | 2.8 | 2 |
| 105 | Evolving Diagnostic and Treatment Strategies for Pediatric CNS Tumors: The Impact of Lipid Metabolism. <i>Biomedicines</i> , 2023, 11, 1365. | 3.2 | 0 |
| 106 | A Novel Variant in the TP53 Gene Causing Liê€Fraumeni Syndrome. <i>Children</i> , 2023, 10, 1150. | 1.5 | 0 |
| 107 | Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project. <i>JCO Precision Oncology</i> , 2023, , . | 3.0 | 2 |
| 108 | TRMT6 gene rs236110 C>A polymorphism increases the risk of Wilms tumor. <i>Gene</i> , 2023, 882, 147646. | 2.2 | 0 |
| 109 | Neurofibromatosis&and schwannomatosis&associated tumors: Approaches to genetic testing and counseling considerations. <i>American Journal of Medical Genetics, Part A</i> , 2023, 191, 2467-2481. | 1.2 | 1 |
| 110 | Pan-cancer atlas of somatic core and linker histone mutations. <i>Npj Genomic Medicine</i> , 2023, 8, . | 3.8 | 3 |
| 111 | Evaluation of Antibiotic Resistance in Pediatric Patients Suffering from Cancer. , 0, , 1-10. | | 1 |
| 112 | Bronchial carcinoid tumors in children and adolescents â€ A report and management considerations from the German MET studies. <i>Lung Cancer</i> , 2023, 183, 107320. | 2.0 | 0 |
| 113 | Socioeconomic status significantly impacts childhood cancer survival in South Africa. <i>Pediatric Blood and Cancer</i> , 2023, 70, . | 1.5 | 1 |
| 114 | The Incidence of Multiple Fusions in a Series of Pediatric Soft Tissue and Bone Tumors. <i>Pediatric and Developmental Pathology</i> , 0, , . | 1.0 | 0 |
| 115 | Identification of hepatoblastoma susceptibility loci in the <sc><i>TRMT6</i></sc> gene from a seven¢er case&control study. <i>Journal of Cellular and Molecular Medicine</i> , 2024, 28, . | 3.6 | 0 |
| 116 | Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. <i>Nature Communications</i> , 2023, 14, . | 12.8 | 0 |
| 117 | Pan-cancer landscape of epigenetic factor expression predicts tumor outcome. <i>Communications Biology</i> , 2023, 6, . | 4.4 | 0 |
| 118 | Germline mutations in pediatric cancer cohort with mixed&ancestry Mexicans. <i>Molecular Genetics & Genomic Medicine</i> , 0, , . | 1.2 | 0 |
| 119 | Precision Oncology in Pediatric Cancer Surgery. <i>Surgical Oncology Clinics of North America</i> , 2024, 33, 409-446. | 1.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 120 | Germline mutations in cancer predisposition genes among pediatric patients with cancer and congenital anomalies. <i>Pediatric Research</i> , 2024, 95, 1346-1355. | 2.3 | 0 |
| 121 | Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases. , 2024, 4, 100140. | | 0 |
| 122 | Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway. <i>British Journal of Cancer</i> , 2024, 130, 513-516. | 6.4 | 1 |
| 123 | Beyond genetics: driving cancer with the tumour microenvironment behind the wheel. <i>Nature Reviews Cancer</i> , 2024, 24, 274-286. | 28.4 | 1 |
| 124 | Advancing Precision Medicine. , 2024, , 1-31. | | 0 |
| 125 | The evolutionary impact of childhood cancer on the human gene pool. <i>Nature Communications</i> , 2024, 15, . | 12.8 | 0 |
| 126 | PÄdiatrische Krebserkrankungen. , 2024, , 301-316. | | 0 |
| 127 | The first pineoblastoma case report of a patient with Sotos syndrome harboring NSD1 germline mutation. <i>BMC Pediatrics</i> , 2024, 24, . | 1.7 | 0 |